natgillin/translations-raw huggingface dataset:
In clinical trials, 2.5% of patients treated with liraglutide developed anti-liraglutide antibodies.
V kliničnih preskušanjih so se pri 2,5 % bolnikov, zdravljenih z liraglutidom, razvila protitelesa proti liraglutidu.
If you are not sure how to split your dose using two pens, then select and inject the dose you need with a new pen.
Če niste prepričani, kako razdeliti odmerek med dva injekcijska peresnika, izberite in injicirajte celoten odmerek z novim injekcijskim peresnikom.
These reactions were usually mild and transitory and the majority disappeared during continued treatment.
Te reakcije so bile ponavadi blage in prehodne, med nadaljevanjem zdravljenja pa so večinoma izzvenele.
Because of lack of experience, Saxenda should not be used during breast-feeding.
Zaradi pomanjkanja izkušenj se zdravila Saxenda med dojenjem ne sme uporabljati.
5 After your injection • Lead the needle tip into the outer needle cap on a flat surface without touching the needle or the outer needle cap.
5 Po injiciranju • Konico igle vstavite v zunanji pokrovček igle na ravni površini, ne da bi se dotaknili igle ali zunanjega pokrovčka igle.
Clear and colourless or almost colourless, isotonic solution; pH=8.15.
Bistra in brezbarvna ali skoraj brezbarvna, izotonična raztopina s pH 8,15.
Patients were randomly allocated to either liraglutide on a daily dose of up to 1.8 mg (4,668) or placebo (4,672), both on a background of standard of care.
Bolniki so bili naključno razporejeni v skupino z dnevnim odmerkom liraglutida do 1,8 mg (4.668) ali placebom (4.672), ki so ju prejemali poleg standardne oskrbe.
Novo Nordisk A/S Novo Allé 2880 Bagsværd Denmark
Novo Nordisk A/S Novo Allé 2880 Bagsvaerd Danska
If there is still no drop, change the needle and repeat step 2 ‘Check the flow' once more.
Če se kapljica še vedno ne pojavi, zamenjajte iglo in še enkrat ponovite korak 2 "Preverite pretok".
More frequent blood testing to determine the ability of your blood to clot may be required.
Morda boste morali opraviti več preiskav krvi, da se oceni sposobnost strjevanja vaše krvi.
If escalation to the next dose step is not tolerated for two consecutive weeks, consider discontinuing treatment.
Če bolnik dviga odmerka ne prenaša dva zaporedna tedna, razmislite o prekinitvi zdravljenja.
The predicted mean weight loss in early responders who complete 1 year of treatment is 11.2% of their baseline body weight (9.7% for males and 11.6% for females).
Napovedana povprečna izguba telesne mase pri bolnikih z zgodnjim odzivom, ki se zdravijo 1 leto, je 11,2 % začetne telesne mase (9,7 % za moške in 11,6 % za ženske).
• Caregivers must be very careful when handling used needles - to prevent needle injury and cross-infection.
• Osebe, ki skrbijo za bolnika, morajo biti pri ravnanju z uporabljenimi iglami zelo pazljive, da se ne bi zbodle in navzkrižno okužile.
Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.
Zdravljenje z zdravilom Saxenda je treba prekiniti po 12 tednih uporabe odmerka 3,0 mg/dan, v kolikor bolniki niso izgubili vsaj 5 % začetne telesne mase.
uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki
When initiating Saxenda, it should be considered to reduce the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia.
Ob uvedbi zdravila Saxenda se mora razmisliti o zmanjšanju odmerka sočasno uporabljanega insulina ali sekretagogov insulina (npr. sulfonilsečnine), da bi zmanjšali tveganje za hipoglikemijo.
• Feeling sick (nausea), being sick (vomiting), diarrhoea, constipation - these usually go away after a few days or weeks.
• občutek slabosti (siljenje na bruhanje), bruhanje, driska, zaprtost - navadno minejo po nekaj dneh ali tednih
Clinical trials suggest that liraglutide improves and sustains beta-cell function, according to HOMA-B and the proinsulin-to-insulin ratio.
Klinična preskušanja kažejo, da liraglutid izboljša in vzdržuje delovanje celic beta, glede na oceno delovanja celic beta s homeostatskim modelom (HOMA-B) in razmerje med proinsulinom in insulinom.
If you lose substantial weight, you are at a risk of gallstones and thereby inflamed gall bladder.
Če izgubite veliko telesne mase, ste podvrženi tveganju za žolčne kamne in posledično za vnetje žolčnika.
Please see section ‘Description of selected adverse reactions' for further information.
Za več informacij glejte podpoglavje "Opis izbranih neželenih učinkov".
Events reported included severe nausea and severe vomiting which are also the expected symptoms of an overdose with liraglutide.
Ti dogodki so vključevali hudo navzeo in hudo bruhanje, ki sta pričakovana simptoma prevelikega odmerjanja z liraglutidom.
Based on the results of population pharmacokinetic analysis, females have 24% lower weight adjusted clearance of liraglutide compared to males.
Glede na rezultate populacijske farmakokinetične analize imajo ženske za 24 % nižji očistek liraglutida, korigiran glede na težo, kot moški.
If a drop still does not appear, dispose of the pen and use a new one.
Če se kapljica še vedno ne pojavi, zavrzite injekcijski peresnik in uporabite novega.
Tell your doctor if you have diabetes.
Obvestite zdravnika, če imate sladkorno bolezen.
The 0 must line up with the dose pointer.
Oznaka 0 mora biti poravnana s kazalnikom odmerka.
The starting dose is 0.6 mg once daily.
Začetni odmerek je 0,6 mg enkrat na dan.
Liraglutide is endogenously metabolised in a similar manner to large proteins without a specific organ as major route of elimination.
Izločanje Endogena presnova liraglutida je podobna presnovi velikih beljakovin in ni nobenega določenega organa, ki bi veljal kot glavna pot izločanja.
The efficacy and safety of liraglutide for weight management in conjunction with reduced calorie intake and increased physical activity were studied in four phase 3 randomised, double-blind, placebocontrolled trials which included a total of 5,358 patients.
Učinkovitost in varnost liraglutida za obvladovanje telesne mase v kombinaciji z zmanjšanim vnosom kalorij in povečano telesno dejavnostjo so preučevali v štirih randomiziranih, dvojno slepih, s placebom nadzorovanih preskušanjih tretje faze, v katera je bilo vključenih 5.358 bolnikov.
Saxenda is unlikely to affect your ability to drive and use machines.
Malo verjetno je, da bi zdravilo Saxenda vplivalo na vašo sposobnost upravljanja vozil in strojev.
The patient should be observed for clinical signs of dehydration and blood glucose should be monitored.
Bolnike je treba opazovati glede kliničnih znakov dehidracije, prav tako pa je treba spremljati koncentracijo glukoze v krvi.
For patients who experience a clinically relevant sustained increase in resting heart rate, treatment with liraglutide should be discontinued.
Bolnikom, pri katerih se pojavi klinično pomembno trajno zvišanje frekvence srčnega utripa v mirovanju, je treba zdravljenje z liraglutidom prekiniti.
Treatment with liraglutide significantly improved systolic blood pressure and waist circumference compared with placebo (tables 3, 4 and 5).
Zdravljenje z liraglutidom je pomembno izboljšalo sistolični krvni tlak in obseg pasu v primerjavi s placebom (preglednice 3, 4 in 5).
A clinically relevant interaction with active substances with poor solubility or narrow therapeutic index such as warfarin cannot be excluded.
Klinično pomembnega medsebojnega delovanja liraglutida in učinkovin s slabo topnostjo in ozkim terapevtskim indeksom, kot je na primer varfarin, ni mogoče izključiti.
• Do not mix Saxenda up with other medicines that you inject (e.g. insulins).
• Zdravila Saxenda ne smete zamešati z drugimi zdravili za injiciranje, ki jih uporabljate (npr. insulini).
You can select up to 3.0 mg per dose.
Izberete lahko največ 3,0 mg na odmerek.
Do not stop using Saxenda without talking to your doctor.
Ne prenehajte uporabljati zdravila Saxenda, ne da bi se o tem prej posvetovali z zdravnikom.
For the proportions of patients losing ≥5/>10% body weight, estimated odds ratios are presented.
Pri deležih bolnikov, ki so izgubili ≥ 5/> 10 % telesne mase, je navedeno ocenjeno razmerje obetov.
Pharmacokinetic properties were assessed in clinical pharmacology studies in the paediatric population with obesity aged 12-17 years (14 patients, body weight 80-122 kg) and 7-11 years (16 patients, body weight 45-87 kg) respectively.
Pediatrična populacija Farmakokinetične lastnosti so ovrednotili v kliničnih farmakoloških študijah pri pediatričnih bolnikih z debelostjo, starih 12-17 let (14 bolnikov s telesno maso 80-122 kg) in 7-11 let (16 bolnikov s telesno maso 45-87 kg).
The fact that substantial weight loss can increase the risk of cholelithiasis and thereby cholecystitis only partially explained the higher rate with liraglutide.
Dejstvo, da lahko znatna izguba telesne mase poveča tveganje za holelitiazo in posledično holecistitis, le deloma obrazloži večjo pojavnost pri liraglutidu.
Patients should be informed of the symptoms of increased heart rate (palpitations or feelings of a racing heartbeat while at rest).
Bolnike je treba seznaniti s simptomi zvišane frekvence srčnega utripa (palpitacije ali občutek hitrega srčnega utripa v mirovanju).
What Saxenda is and what it is used for What you need to know before you use Saxenda How to use Saxenda
Kaj je zdravilo Saxenda in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Saxenda Kako uporabljati zdravilo Saxenda
Substances added to Saxenda may cause degradation of liraglutide.
Snovi, dodane zdravilu Saxenda, lahko povzročijo razgradnjo liraglutida.
Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar.
Zdravnik vam bo morda prilagodil odmerek zdravila za sladkorno bolezen, da prepreči pojav nizkega krvnega sladkorja.
The vast majority of these had established cardiovascular disease.
Velika večina bolnikov je imela dokazano srčno-žilno bolezen.
Talk to your doctor if you have or have had a disease of the pancreas.
Posvetujte se z zdravnikom, če imate ali ste kdaj imeli bolezen trebušne slinavke.
• However, if more than 12 hours have passed since you should have used Saxenda, skip the missed dose and inject your next dose the following day at the usual time.
• Če pa je minilo že več kot 12 ur, odkar bi morali uporabiti zdravilo Saxenda, preskočite ta odmerek in injicirajte naslednji odmerek kot ponavadi naslednji dan.
Based on the exposure response data, no dose adjustment is necessary based on gender.
Glede na podatke o odzivu na zdravilo, prilagoditev odmerka glede na spol ni potrebna.
The mean clearance following subcutaneous administration of liraglutide is approximately 0.9-1.4 L/h with an elimination half-life of approximately 13 hours.
Povprečen očistek po subkutani aplikaciji odmerka liraglutida je približno 0,9-1,4 l/h, eliminacijski razpolovni čas pa je približno 13 ur.
Patients should be informed of the characteristic symptoms of cholelithiasis and cholecystitis.
Bolnike je treba seznaniti z značilnimi simptomi holelitiaze in holecistitisa.
Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of
Zdravilo Saxenda se uporablja kot dodatno zdravljenje k dieti z zmanjšanim vnosom kalorij in povečani telesni dejavnosti za obvladovanje telesne mase pri odraslih bolnikih z začetnim indeksom telesne mase (ITM):
The liraglutide exposure in adolescents (age 12-17 years) was similar to that in adults with obesity.
Pri mladostnikih (starih 12-17 let) je bila izpostavljenost liraglutidu podobna kot pri odraslih z debelostjo.
Always watch the dose counter to know how many mg you inject.
Vedno glejte števec odmerka, da vidite, koliko mg injicirate.
Contents of the pack and other information What Saxenda contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Saxenda
The safety and efficacy of liraglutide for weight management have not been established in patients: - aged 75 years or more, - treated with other products for weight management, - with obesity secondary to endocrinological or eating disorders or to treatment with medicinal products that may cause weight gain, - with severe renal impairment, - with severe hepatic impairment.
Varnost in učinkovitost liraglutida za obvladovanje telesne mase nista ugotovljeni pri bolnikih, ki: - so stari 75 let ali več, - uporabljajo druga zdravila za obvladovanje telesne mase, - imajo sekundarno debelost zaradi endokrinih ali prehranskih motenj ali zaradi zdravljenja z zdravili, ki lahko povzročijo porast telesne mase,
The primary endpoint was the time from randomisation to first occurrence of any major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.
Primarni opazovani dogodek je bil čas od randomizacije do prvega pojava katerega od pomembnih srčno-žilnih neželenih dogodkov (Major Adverse Cardiovascular Events (MACE)): smrt zaradi srčno-žilnih zapletov, miokardni infarkt brez smrtnega izida ali možganska kap brez smrtnega izida.
If you feel dizziness be extra careful while driving or using machines.
Če se vam pojavi omotica, morate biti pri upravljanju vozil in strojev še posebno previdni.
This medicine is not recommended if you have a severe stomach or gut problem which results in delayed stomach emptying (called gastroparesis), or if you have an inflammatory bowel disease.
Uporaba zdravila ni priporočljiva, če imate hude težave z želodcem ali črevesjem in se vam zato želodec počasneje prazni (gastropareza) ali če imate kronično vnetno črevesno bolezen.
Liraglutide lowers body weight in humans mainly through loss of fat mass with relative reductions in visceral fat being greater than for subcutaneous fat loss.
Liraglutid zmanjšuje telesno maso pri ljudeh v glavnem z zmanjševanjem mase maščobe, pri čemer je delež izgube visceralne maščobe večji od deleža izgube podkožne maščobe.
Saxenda was evaluated for safety in 5 double-blind, placebo controlled trials that enrolled 5,813 obese patients or overweight patients with at least one weight-related comorbidity.
Varnost zdravila Saxenda so ocenili v 5 dvojno slepih, s placebom nadzorovanih preskušanjih, v katera je bilo vključenih 5.813 bolnikov z debelostjo ali bolnikov s prekomerno telesno maso, ki so imeli vsaj eno z debelostjo povezano bolezen.
Saxenda is for subcutaneous use only.
Zdravilo Saxenda je namenjeno zgolj subkutani uporabi.
Change in Body Weight (%)
Sprememba telesne mase (%)
Cardiometabolic risk factors
Srčno-presnovni dejavniki tveganja
• increase of pancreatic enzymes, such as lipase and amylase.
• zvišanje koncentracije encimov trebušne slinavke (npr. lipaze in amilaze)
• you are taking warfarin or other medicines by mouth that reduce your blood clotting (anticoagulants).
• jemljete varfarin ali druga peroralna zdravila proti strjevanju krvi (antikoagulanti).
The dose selector changes the dose.
Z izbirnikom odmerka spreminjate odmerek.
Cartridge (type 1 glass) with a plunger (bromobutyl) and a laminate rubber sheet (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polyacetal, polycarbonate and acrylonitrile butadiene styrene.
Vložek (steklo tipa 1) z batom (brombutil) in laminatno gumijasto prevleko (brombutil/poliizopren) v večodmernem napolnjenem injekcijskem peresniku iz polipropilena, poliacetala, polikarbonata in akrilonitril butadien stirena.
Liraglutide exposure was not studied in patients with body weight >234 kg.
Izpostavljenosti liraglutidu pri bolnikih s telesno maso > 234 kg niso merili.
Increased amylase *Hypoglycaemia (based on self-reported symptoms by patients and not confirmed by blood glucose measurements) reported in patients without type 2 diabetes mellitus treated with Saxenda in combination with diet and exercise.
povečana koncentracija amilaze *Hipoglikemija (ugotovljena na osnovi simptomov, ki so jih opazili bolniki, in ni potrjena z meritvami glukoze v krvi) pri bolnikih brez sladkorne bolezni tipa 2, zdravljenih z zdravilom Saxenda v kombinaciji z dieto in telesno vadbo.
EXP Discard pen 1 month after first use
EXP Injekcijski peresnik zavrzite 1 mesec po prvi uporabi.
Acute pancreatitis has been observed with the use of GLP-1 receptor agonists.
Pri uporabi agonistov receptorjev GLP-1 je bil opažen akutni pankreatitis.
Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) analogue with 97% amino acid sequence homology to endogenous human GLP-1.
Liraglutid je acilirani humani analog glukagonu podobnega peptida-1 (GLP-1) s 97 % homologijo zaporedja aminokislin glede na endogeni humani GLP-1.
If your pen is already in use, go to step 3 ‘Select your dose'.
Če je injekcijski peresnik že bil uporabljen, glejte korak 3 "Izbira odmerka".
Only the dose counter and dose pointer will show how many mg you select per dose.
Le števec odmerka in kazalnik odmerka kažeta, koliko mg izberete na odmerek.
BMI (Body Mass Index) is a measure of your weight in relation to your height.
ITM (indeks telesne mase) je razmerje med vašo maso in višino.
Patients ≥65 years of age may experience more gastrointestinal effects when treated with Saxenda.
Bolniki, starejši od 65 let, imajo lahko med zdravljenjem z zdravilom Saxenda več neželenih učinkov na prebavilih.
There is little experience with this medicine in patients of 75 years and older.
Izkušenj z uporabo tega zdravila pri bolnikih, starih 75 let in več, je malo.
Use a calculator to plan the doses as instructed by your doctor or nurse.
Za načrtovanje odmerkov uporabite računalo, v skladu z navodili zdravnika ali medicinske sestre.
Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop anti-liraglutide antibodies following treatment with liraglutide.
Glede na morebitne imunogenske lastnosti zdravil, v katerih so beljakovine ali peptidi, se lahko po zdravljenju z liraglutidom pri bolnikih razvijejo protitelesa proti liraglutidu.
If you use more Saxenda than you should, talk to a doctor or go to a hospital straight away.
Če ste uporabili večji odmerek zdravila Saxenda, kot bi smeli Če ste uporabili večji odmerek zdravila Saxenda, kot bi smeli, se nemudoma posvetujte z zdravnikom ali odidite v bolnišnico.
Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues.
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, analogi glukagonu podobnega peptida1 (GLP-1).
This medicine contains less than 1 mmol sodium (23 mg) per dose, that it is to say essentially ‘sodium-free'.
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni "brez natrija".
Only a minor part of the administered radioactivity was excreted as liraglutide-related metabolites in urine or faeces (6% and 5%, respectively).
Samo manjši del aplicirane radioaktivnosti se je v urinu (6 %) ali blatu
Events were isolated and the majority resolved during continued treatment with Saxenda.
To so bili posamični primeri in so med nadaljevanjem zdravljenja z zdravilom Saxenda večinoma izzveneli.
Diet and exercise
Dieta in telesna vadba
• ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
• ≥ 27 kg/m² do < 30 kg/m² (prekomerna telesna masa), ki imajo sočasno vsaj eno z debelostjo povezano bolezen, kot npr. disglikemija (predstopnja sladkorne bolezni (preddiabetes) ali sladkorna bolezen tipa 2), hipertenzija, dislipidemija ali obstruktivna apneja med spanjem.
*human glucagon-like peptide-1 (GLP-1) analogue produced by recombinant DNA technology in Saccharomyces cerevisiae.
*analog humanega glukagonu podobnega peptida-1 (GLP-1 - glucagon-like peptide-1), pridobljen s tehnologijo rekombinantne DNA iz Saccharomyces cerevisiae.
If an anaphylactic reaction is suspected, liraglutide should be discontinued and treatment should not be restarted (see section 4.3).
V primeru suma na anafilaktično reakcijo je treba zdravljenje z liraglutidom prekiniti in se ga ne sme več uvesti (glejte poglavje 4.3).
The estimated time to onset of type 2 diabetes mellitus for patients treated with liraglutide 3.0 mg was 2.7 times longer (with a 95% confidence interval of [1.9, 3.9]), and the hazard ratio for risk of developing type 2 diabetes mellitus was 0.2 for liraglutide versus placebo.
Pri bolnikih, ki so se zdravili z liraglutidom v odmerku 3,0 mg, je bil ocenjeni čas do nastopa sladkorne bolezni tipa 2 2,7-krat daljši (95 % interval zaupanja [1,9; 3,9]), razmerje ogroženosti za tveganje razvoja sladkorne bolezni tipa 2 pa je za liraglutid v primerjavi s placebom znašalo 0,2.
Patients with heart failure
Bolniki s srčnim popuščanjem
The change in heart rate was reversible upon discontinuation of liraglutide (see section 4.4).
Sprememba frekvence srčnega utripa je bila po ukinitvi liraglutida reverzibilna (glejte poglavje 4.4).
Do not use Saxenda after the expiry date which is stated on the pen label and carton after ‘EXP'.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki na injekcijskem peresniku in na škatli poleg oznake "EXP".
Mean baseline HbA1c was 8.7 and had improved after 3 years by 1.2 % in patients assigned to liraglutide and by 0.8 % in patients assigned to placebo.
V izhodišču je bila povprečna vrednost HbA1c 8,7, ki se je po 3 letih izboljšala za do 1,2 % pri bolnikih, ki so prejemali liraglutid in za do 0,8 % pri bolnikih, ki so prejemali placebo.
When your pen contains less than 3.0 mg the dose counter stops before 3.0 is shown.
Ko injekcijski peresnik vsebuje manj kot 3,0 mg, se števec odmerka ustavi, preden se pokaže 3,0.
The absorption of liraglutide following subcutaneous administration was slow, reaching maximum concentration approximately 11 hours post dosing.
Absorpcija liraglutida po subkutanem odmerku je počasna; največjo koncentracijo doseže približno
If the dose counter stops before 3.0 mg, there is not enough solution left for a full dose of 3.0 mg.
Če se števec odmerka ustavi pred 3,0 mg, to pomeni, da ni več dovolj raztopine za celotni odmerek 3,0 mg.
An extra dose or increase in dose should not be taken to make up for the missed dose.
Ne sme uporabiti dodatnega odmerka ali povečati odmerka, da bi nadoknadil zamujen odmerek.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity or genotoxicity.
Neklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
The glucose-lowering effect is more pronounced in patients with pre-diabetes and diabetes compared to patients with normoglycaemia.
Učinek zmanjšanja koncentracije glukoze je bolj izražen pri bolnikih s preddiabetesom in pri bolnikih s sladkorno boleznijo, v primerjavi z bolniki z normoglikemijo.
You should only continue using Saxenda if you have lost at least 5% of your initial body weight after 12 weeks on the 3 mg/day dose (see section 3).
Z uporabo zdravila Saxenda lahko nadaljujete le v primeru, da ste po 12 tednih uporabe odmerka 3 mg/dan izgubili vsaj 5 % začetne telesne mase (glejte poglavje 3).
However, it is preferable that Saxenda is injected around the same time of the day, when the most convenient time of the day has been chosen.
Kljub temu je zdravilo Saxenda priporočljivo injicirati vsak dan ob približno istem času, ki bolniku najbolj ustreza.
• ≥30 kg/m² (obese), or
• ≥ 30 kg/m² (debelost) ali
Liraglutide regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake.
Liraglutid uravnava apetit, tako da poveča občutek sitosti in potešenosti ter zmanjša občutek lakote, kar vodi v zmanjšan vnos hrane.